[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340258-105":59,"doc-detail-340258-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","new-small-molecule-serca-inhibitors-enhance-treatment-efficacy-in-lenvatinib-resistant-papillary-thyroid-cancer","New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer","","Papillary thyroid cancer (PTC) is often curable, yet drug resistance drives metastasis and recurrence, undermining therapy and increasing mortality. For lenvatinib-resistant PTC, the molecular mechanisms, especially those shaped by epigenetic reprogramming, remain insufficiently defined. This study investigated small-molecule SERCA inhibitors by comparing patient-derived lenvatinib-resistant versus sensitive cells. SERCA upregulation was identified and two in silico candidates were tested in combination with lenvatinib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-small-molecule-serca-inhibitors-enhance-treatment-efficacy-in-lenvatinib-resistant-papillary-thyroid-cancer/340258/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-small-molecule-serca-inhibitors-enhance-treatment-efficacy-in-lenvatinib-resistant-papillary-thyroid-cancer/340258.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is lenvatinib resistance a major challenge in papillary thyroid cancer?","Question",{"text":112,"@type":113},"Resistance to anticancer drugs can lead to metastasis and recurrence, causing treatment failure and ultimately contributing to patient mortality.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence suggested SERCA as a potential therapeutic target in lenvatinib-resistant PTC?",{"text":117,"@type":113},"The study observed increased sarco/endoplasmic reticulum calcium ATPase (SERCA) levels in patient-derived lenvatinib-resistant PTC cells compared with lenvatinib-sensitive cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the SERCA inhibitors affect treatment outcomes when combined with lenvatinib?",{"text":121,"@type":113},"Two SERCA inhibitor candidates identified via in silico screening reduced cell viability in patient-derived lenvatinib-resistant PTC cells and produced significant tumor shrinkage in a xenograft tumor model when used with lenvatinib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340258,1790498306,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nNew Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer  \nJungmin Kim 1, Hang-Seok Chang 2, Hyeok Jun Yun 2, Ho-Jin Chang 2,† and Ki Cheong Park 1, *,†  \nCitation: Kim, J.; Chang, H.-S.; Yun, H.J.; Chang, H.-J.; Park, K.C. New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer. Int. J. Mol. Sci. 2024, 25, 10646. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms251910646  \nAcademic Editors: Nam Deuk Kim and Daniela Grimm  \nReceived: 26 June 2024  \nRevised: 27 September 2024  \nAccepted: 30 September 2024  \nPublished: 3 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Surgery, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea; [jm_kim@yuhs.ac](jm_kim@yuhs.ac)  \n2 Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Institute of Refractory Thyroid Cancer, Yonsei University College of Medicine, Seoul 06273, Republic of Korea; [surghsc@yuhs.ac](surghsc@yuhs.ac) (H.-S.C.); [gsyhj@yuhs.ac](gsyhj@yuhs.ac) (H.J.Y.); [docjang@yuhs.ac](docjang@yuhs.ac) (H.-J.C.)  \n* Correspondence: [ggiru95@yuhs.ac](ggiru95@yuhs.ac)[ ](ggiru95@yuhs.ac)† These authors contributed equally to this work.  \nAbstract: Papillary thyroid cancer (PTC) is one of the most treatable forms of cancer, with many cases being fully curable. However, resistance to anticancer drugs often leads to metastasis or recurrence, contributing to the failure of cancer therapy and, ultimately, patient mortality. The mechanisms underlying molecular differences in patients with metastatic or recurrent PTC, particularly those resistant to anticancer drugs through epigenetic reprogramming, remain poorly understood. Consequently, refractory PTC presents a critical challenge, and effective therapeutic strategies are urgently needed. Therefore, this study aimed to identify small-molecule inhibitors to enhance treatment efficacy in lenvatinib-resistant PTC. We observed an increase in sarco/endoplasmic reticulum calcium ATPase (SERCA) levels in patient-derived lenvatinib-resistant PTC cells compared with lenvatinib-sensitive ones, highlighting its potential as a therapeutic target. We subsequently identified two SERCA inhibitors [candidates 40 (isoflurane) and 42 (ethacrynic acid)] through in silico screening. These candidates demonstrated significant tumor shrinkage in a xenograft tumor model and reduced cell viability in patient-derived lenvatinib-resistant PTC cells when used in combination with lenvatinib. Our findings have potential clinical value for the development of new combination therapies to effectively target highly malignant, anticancer drug-resistant cancers.  \nKeywords: papillary thyroid cancer; lenvatinib; drug-resistant; SERCA inhibitors  \n1. Introduction  \nThyroid cancer (TC) is the most common endocrine malignancy, characterized by the development of cancer cells in the thyroid gland in the neck [1,2] . TC is typically classified into four subtypes: medullary TC (MTC), follicular TC (FTC), papillary TC (PTC), and anaplastic TC (ATC) [3] . Clinically, TCs are categorized as either undifferentiated or differentiated [4,5] . Well-differentiated TC generally has a favorable prognosis, whereas poorly differentiated or undifferentiated TC (PDTC and UTC) is rare and associated with a poor prognosis [6,7] . Refractory TC, such as PDTC and UTC, exhibits resistance to anticancer drugs due to epigenetic reprogramming, leading to recurrence or metastasis and ultimately patient death [8] . Despite clear clinical behaviors, ","cbCaikZCZv8eL29c","https://ap.wps.com/l/cbCaikZCZv8eL29c","pdf",2887664,16,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why is lenvatinib resistance a major challenge in papillary thyroid cancer?\",\"answer\":\"Resistance to anticancer drugs can lead to metastasis and recurrence, causing treatment failure and ultimately contributing to patient mortality.\"},{\"question\":\"What evidence suggested SERCA as a potential therapeutic target in lenvatinib-resistant PTC?\",\"answer\":\"The study observed increased sarco/endoplasmic reticulum calcium ATPase (SERCA) levels in patient-derived lenvatinib-resistant PTC cells compared with lenvatinib-sensitive cells.\"},{\"question\":\"How did the SERCA inhibitors affect treatment outcomes when combined with lenvatinib?\",\"answer\":\"Two SERCA inhibitor candidates identified via in silico screening reduced cell viability in patient-derived lenvatinib-resistant PTC cells and produced significant tumor shrinkage in a xenograft tumor model when used with lenvatinib.\"}]","New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer | PDF",1790035319,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f3421ae5a0169d8861c52bf1f37827f.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6da5a1af36df27106dc772b1cbd59881.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3fac9bc2c0f7e482e23f869ec396e96.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9c070f0e7c158c22ace38ed3a007125.webp",980,1385]